[
1. Didkowska J, Wojciechowska U, Czaderny K. Nowotwory złośliwe w Polsce w 2017 roku. Krajowy Rejestr Nowotworów. Warszawa: Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, 2019.
]Search in Google Scholar
[
2. Plagens-Rotman K, Chmaj-Wierzchowska K, Pięta B, Bojar I. Modifiable lifestyle factors and ovarian cancer incidence in women. Ann. Agric. Environ. Med. 2018; 1: 36-40.
]Search in Google Scholar
[
3. Kurman RJ, Shih IM. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. Am. J. Surg. Pathol. 2010; 34: 433-443.
]Search in Google Scholar
[
4. Budiana ING, Angelina M, Pemayun TGA. Varian cancer: Pathogenesis and current recommendations for prophylactic surgery. J. Turk. Ger. Gynecol. Assoc. 2019; 26: 47-54.
]Search in Google Scholar
[
5. Mavaddat N, Peock S, Frost D. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of embrace. J. Natl. Cancer. Inst. 2013; 5: 812-822.
]Search in Google Scholar
[
6. Dowdy SC, Stefanek M, Hartmann LC. Surgical risk reduction: prophylactic salpingooophorectomy and prophylactic mastectomy. Am. J. Obstet. Gynecol. 2004; 191: 1113-1123.
]Search in Google Scholar
[
7. Koh SC, Huak CY, Lutan D, et al. Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. J. Gynecol. Oncol. 2012; 23: 175-181.
]Search in Google Scholar
[
8. Kossai M, Leary A, Scoazec J-Y, Genestie C. Ovarian Cancer; A heterogeneous disease. Pathobiology. 2018; 85(1-2): 41-49.
]Search in Google Scholar
[
9. Xinxin Z, Jinghe L. Programmed death-1Pathway Blockade Produces a Synergistic Antitumor Effect Combined Application In Ovarian Cancer. J. Gynecol. Oncol. 2017; 5: 64.
]Search in Google Scholar
[
10. Eisenhauer EA. Real-world evidence. In the treatment of ovaria cancer. Ann. Oncol. 2011; 1(8): 28.
]Search in Google Scholar
[
11. Vargas AN. Natural history of ovarian cancer. J. Cancer. Sci. Ther. 2014; 6: 247-252.
]Search in Google Scholar
[
12. Lalrinpuii E, Bhageerathy PS, Sebastian A. Ovarian Cancer in Young Women. Peedicayil. A Indian. J. Surg. Oncol. 2017; 4: 540-547.
]Search in Google Scholar
[
13. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 9: 1274-1284.
]Search in Google Scholar
[
14. Kruczała MA, Grela-Wojewoda A, Cedrych I. PARP inhibitors in the ovarian cancer therapy. Ginekol. Pol. 2016; 87: 131-134.
]Search in Google Scholar
[
15. Górski B, Byrski T, Huzarski T, et.al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 2000; 6: 1963-1968.
]Search in Google Scholar
[
16. Riedlova P, Janoutova J, Hermanova B. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Mol. Biol. Rep. 2020; 4: 2763-2769.
]Search in Google Scholar
[
17. Plagens-Rotman K, Chuchracki M, Piskorz-Szymendera M, et al. Reproductive factors and the endometrial cancer morbidity. Eur. J. Gynaecol. Oncol. 2019; 3: 431-436.
]Search in Google Scholar
[
18. Plagens-Rotman K, Piskorz-Szymendera M, Chmaj-Wierzchowska K, Pięta B. Breast cancer - Analysis of the selected risk factors. Eur. J. Gynaecol. Oncol. 2017; 3: 425-430.
]Search in Google Scholar
[
19. Plagens-Rotman K, Żak E, Pięta B. Odds ratio analysis in women with endometrial cancer. Prz. Menopauz. 2016; 1: 12-19.
]Search in Google Scholar
[
20. Act of November 6, 2008 on patient rights and the Ombudsman for Patient Rights (consolidated text of the Journal of Laws of 2020, item 849).
]Search in Google Scholar
[
21. the Code of Medical Ethics (https://nil.org.pl/uploaded_images/1574857770_kodeks-etyki-lekarskiej.pdf, access: 11.06.2020).
]Search in Google Scholar
, 